This is a preprint.
Rare variants in genes coding for components of the terminal pathway of the complement system in preeclampsia
- PMID: 38645143
- PMCID: PMC11030519
- DOI: 10.21203/rs.3.rs-4121735/v1
Rare variants in genes coding for components of the terminal pathway of the complement system in preeclampsia
Update in
-
Understanding rare genetic variants within the terminal pathway of complement system in preeclampsia.Genes Immun. 2025 Feb;26(1):22-26. doi: 10.1038/s41435-024-00310-6. Epub 2024 Dec 17. Genes Immun. 2025. PMID: 39690307 Free PMC article.
Abstract
Preeclampsia is a common multifactorial disease of pregnancy. Dysregulation of the complement activation is among emerging candidates responsible for disease pathogenesis. In a targeted exomic sequencing study we identified 14 variants within nine genes coding for components of the membrane attack complex (MAC, C5b-9) that are associated with preeclampsia. We found two rare missense variants in the C5 gene that predispose to preeclampsia (rs200674959: I1296V, OR (CI95) = 24.13 (1.25-467.43), p-value = 0.01 and rs147430470: I330T, OR (CI95) = 22.75 (1.17-440.78), p-value = 0.01). In addition, one predisposing rare variant and one protective rare variant were discovered in C6 (rs41271067: D396G, OR (CI95) = 2.93 (1.18-7.10), p-value = 0.01 and rs114609505: T190I, 0.02 OR (CI95) = 0.47 (0.22-0.92), p-value = 0.02). The results suggest that variants in terminal complement pathway predispose to preeclampsia.
Conflict of interest statement
Competing interests: AJ serves on the Scientific advisory boards of Alexion, AstraZeneca Rare Disease, and Novartis International AG, and serves as a consultant for Dianthus Therapeutics and Aurinia Pharmaceuticals. She has been a principal investigator for Apellis Pharmaceuticals and Novartis International AG. She also received royalty from UptoDate. HL received honoraria from Orion Corporation. JPA is part of the Scientific Advisory Board of Complement Corporation and Kypha, Inc., Scientific Advisory Board. Furthermore, he served as a consultant in Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc., Biothera and Clinical Pharmacy Services, CDMI. SM received honoraria from Alexion, AstraZeneca Rare Disease, Biogen, Merck, Pfizer, and UCB, and research funding from Alexion.
Figures
References
-
- Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544.e1–544.e12. - PubMed
-
- Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013;170(1):1–7. - PubMed
-
- Van Lerberghe W, Manuel A, Matthews Z, Cathy W. The World Health Report 2005 - make every mother and child count. World Health Organization; 2005.
-
- Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7. - PubMed
-
- Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet. 2000;91(4):256–60. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
